Skip to content
OpenCapital
Get started

Rapid Micro Biosystems RPID Cash & Equivalents

Cash & Equivalents at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
$198.2M-14.5%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$509M-2.7%
Pacific Biosciences of California logo
Pacific Biosciences of CaliforniaPACB
$57.86M-4.7%
iRadimed logo
iRadimedIRMD
$56.37M+12.0%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
$188.67M-46.9%
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$521.4M+29.0%

Other financials

Income statement

See full
Revenue$8.0M+11.1%
Gross profit$371.0K-8.2%
Operating income-$13.9M-18.8%
Net income-$14.3M-26.7%
EPS (diluted)-$0.31-19.2%

Balance sheet

See full
Total debt$23.8M+301%
Total equity$20.4M-68.9%
Total assets$62.4M-27.0%

Cash flow

See full
Operating cash flow-$15.1M-66.1%
CapEx$394.0K+23.5%
Free cash flow-$15.5M-64.7%

Valuation

See full
Market cap$86.19M-43.5%
Enterprise value$95.86M-31.3%
P/S2.5×-2.5×

Profitability

See full
Operating margin-144.2%-12.7pp
Net margin-145.8%-5.0pp
FCF margin-110.5%-14.9pp

Returns & leverage

See full
Return on equity-116.7%-620pp
Debt / equity1.2×+1.1×
Current ratio2.6×-2.0×

Where this comes from

Reported directly by Rapid Micro Biosystems in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Rapid Micro Biosystems’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapid Micro Biosystems's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapid Micro Biosystems's cash & equivalents?
Rapid Micro Biosystems (RPID) reported cash & equivalents of $14.1M in Q1 2026.
How has Rapid Micro Biosystems's cash & equivalents changed year-over-year?
Rapid Micro Biosystems's cash & equivalents decreased by 26.8% year-over-year, from $19.27M to $14.1M.
What is the long-term trend for Rapid Micro Biosystems's cash & equivalents?
Over 5 years (2020 to 2025), Rapid Micro Biosystems's cash & equivalents has grown at a -7.6% compound annual growth rate (CAGR), from $30.18M to $20.31M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.